Christian Klein
PD
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (62)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
T-Cell Engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in scRNA-seq technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment (TME). In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (PBMC) from glofitamab-treated R/R B-NHL patients, achieving complete metabolic responders (CMR) or progressive metabolic disease (PMD). Our findings reveal that the maintenance of naive-like ("fresher") T-cell states (particularly the fresher cytotoxic T cells) at early timepoints is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared to non-responders. Furthermore, the analysis of patient PBMCs and intra-tumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB co-stimulation translated into increased proportions of intra-tumor T cells having a "fresher", naive-like phenotype, ultimately leading to stronger anti-tumor efficacy. Taken together, our findings underscore the therapeutic relevance of "fresher" naive-like T-cell states and the potential of leveraging 4-1BB co-stimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (30)
Nicola Ternette
Professor
University of Dundee
Jennifer Gommerman
Full Professor
University of Toronto
Luciano A Masullo
Project Leader
Max Planck Institute of Biochemistry
Thomas Nerreter
University Hospital Würzburg
Sara Labiano
Group Leader
Center for Applied Medical Research
Felix Luessi
University Medical Center of the Johannes Gutenberg University Mainz
Henry Kao
Group Head, Biomarker Sciences
-
Solange Peters
-
Roberto Villaseñor
Lab Head
F Hoffmann-La Roche AG
Anthony J. Saviola
University of Colorado Anschutz Medical Campus
Yuwen Zhu
Professor with tenure
University of Colorado School of Medicine
Anne‐Katrin Pröbstel
-
Pilar Garrido López
Head Medical Oncology Department
HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL
David John
Goethe University Frankfurt
Christian Münz
University of Zurich
Jessica Hartmann
Senior Researcher and Regulatory Assessor
Paul-Ehrlich-Institut
Alfred Zippelius
University of Basel
Ralf Jungmann
Professor
Ludwig-Maximilians-Universität München
Andrés Cervantes
Professor of Medicine
University of Valencia
Ignacio Melero
Kidani Professor of Cancer Immuno-Therapeutics
University of Oxford
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Viktor Koelzer
Medical Co-Director, Professor of Experimental Pathology
University of Zurich
Sana D. Karam
Professor and Department Chair
Washington University in St. Louis
Michael Thomas Sandholzer
University of Basel
Joanna Kalucka
Assistant Professor
Aarhus University
Kristoffer Rohrberg
Ass. Professor
Faculty of Health and Medical Sciences, University of Copenhagen
Heinz Läubli
University of Basel
Frauke Zipp
Head of Department
Johannes Gutenberg Universität Universitätsmedizin
Sara Colombetti
Global Head of Oncology Discovery Pharmacology
Roche Diagnostics
Nicole Joller
Professor for Immunology
University of Zurich
Make your next move.
Prepare your application
Review drafts before you send them.